G9036 HCPCS Level II Code: Rimantadine hydrochloride, oral, brand, per 100 mg (for use in a medicare-approved demonstration project)
Medicare Coverage & Payment
- CMS short descriptor: Rimantadine hcl, brand
- Medicare coverage: Carrier judgment (CMS coverage code C)
- Payment category: Service not separately priced (pricing indicator 00)
- BETOS: O1E — Other drugs
- Last CMS action effective: January 1, 2020
- Terminated: December 31, 2019
Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.
Code Set: Removed from the code set — not valid on or after January 1, 2020.
Contextual Map
Every relationship of G9036 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.
Nearest codes (40)
- G9003 — Coordinated care fee, risk adjusted high, initial[Sibling]— CMS HCPCS Level II code set
- G9004 — Coordinated care fee, risk adjusted low, initial[Sibling]— CMS HCPCS Level II code set
- G9005 — Coordinated care fee, risk adjusted maintenance[Sibling]— CMS HCPCS Level II code set
- G9006 — Coordinated care fee, home monitoring[Sibling]— CMS HCPCS Level II code set
- G9007 — Coordinated care fee, scheduled team conference[Sibling]— CMS HCPCS Level II code set
- G9008 — Coordinated care fee, physician coordinated care oversight services[Sibling]— CMS HCPCS Level II code set
- G9009 — Coordinated care fee, risk adjusted maintenance, level 3[Sibling]— CMS HCPCS Level II code set
- G9010 — Coordinated care fee, risk adjusted maintenance, level 4[Sibling]— CMS HCPCS Level II code set
- and 32 more
Change history (2)
- January 1, 2020 — Removed from the code set [Change history]— CMS release files (code change ledger)
- and 1 more
Sources for this page
Codes, titles, notes, index terms and mappings on this page are transcribed from the datasets below. Relationships MedCoder computed and text MedCoder wrote are labelled where they appear.
- Code, descriptors, coverage and pricing attributes Official source data
- CMS HCPCS Alpha-Numeric (ANWEB) release — July 2026 quarterly update Release, file and checksum · Publisher’s page
- Change history and date-of-service validity Official source data
- CMS HCPCS quarterly update files, ingested into the change ledger Release, file and checksum · Publisher’s page
- Comparisons, relationships and the contextual map MedCoder structured relationship
- Computed by MedCoder from the tabular notes and tables above; every derived relationship is marked as derived where it appears
- Summary and FAQ answers MedCoder explanation
- Written by MedCoder to explain the sources above: drafted with AI assistance, checked by a person against the release files, and labelled as MedCoder text where it appears. Not official text.
Labels on this page: Official source data · MedCoder structured relationship · MedCoder explanation. How to read the labels · All data sources and release dates
Change history
- January 1, 2020Removed from the code setRimantadine hydrochloride, oral, brand, per 100 mg (for use in a medicare-approved demonstration project)
- December 1, 2004Added to the code setRimantadine hydrochloride, oral, brand, per 100 mg (for use in a medicare-approved demonstration project)
Nearest Codes in This Family
Official HCPCS Level II classifications closest to G9036 in its code family, with their registry titles.
- G9019 — Oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project)
- G9020 — Rimantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)
- G9033 — Amantadine hydrochloride, oral brand, per 100 mg (for use in a medicare-approved demonstration project)
- G9034 — Zanamivir, inhalation powder, administered through inhaler, brand, per 10 mg (for use in a medicare-approved demonstration project)
- G9035 — Oseltamivir phosphate, oral, brand, per 75 mg (for use in a medicare-approved demonstration project)
- G9037 — Interprofessional telephone/internet/electronic health record clinical question/request for specialty recommendations by a treating/requesting physician or other qualified health care professional…
- G9038 — Co-management services with the following elements: new diagnosis or acute exacerbation and stabilization of existing condition; condition which may benefit from joint care planning; condition for…
- G9050 — Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a medicare-approved demonstration project)
- G9051 — Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing…
- G9052 — Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer…